354 related articles for article (PubMed ID: 26504401)
1. Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases.
Menzella F; Lusuardi M; Galeone C; Taddei S; Zucchi L
J Asthma Allergy; 2015; 8():105-14. PubMed ID: 26504401
[TBL] [Abstract][Full Text] [Related]
2. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
3. The spectrum of therapeutic activity of mepolizumab.
Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
[No Abstract] [Full Text] [Related]
4. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
5. Targeting eosinophils: severe asthma and beyond.
Caminati M; Menzella F; Guidolin L; Senna G
Drugs Context; 2019; 8():212587. PubMed ID: 31391853
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
8. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
9. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab versus placebo for asthma.
Powell C; Milan SJ; Dwan K; Bax L; Walters N
Cochrane Database Syst Rev; 2015 Jul; (7):CD010834. PubMed ID: 26214266
[TBL] [Abstract][Full Text] [Related]
11. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
12. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
Busse WW; Ring J; Huss-Marp J; Kahn JE
J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
[TBL] [Abstract][Full Text] [Related]
13. Anti-interleukin-5 antibody therapy in asthma and allergies.
Corren J
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):565-70. PubMed ID: 21971335
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
[TBL] [Abstract][Full Text] [Related]
15. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.
Roufosse F
Front Med (Lausanne); 2018; 5():49. PubMed ID: 29682504
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
18. Mepolizumab treatment for asthma.
Robinson DS
Expert Opin Biol Ther; 2013 Feb; 13(2):295-302. PubMed ID: 22998420
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
Iino Y; Takahashi E; Ida S; Kikuchi S
Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma.
Russell R; Brightling C
Expert Rev Respir Med; 2016 Jun; 10(6):607-17. PubMed ID: 27058452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]